A recent rocket launch lofted satellites for a Chinese constellation mimicking that of SpaceX, which was slammed this weekend by a top U.S. lawmaker.
Category: satellites – Page 21
SpaceX recently tested Starlink’s Direct to Cell satellites and posted on Elon Musk’s X platform.
The test X post simply said: “This post was sent through a SpaceX Direct to Cell satellite.”
SpaceX’s Director of Satellite Engineering provided more information about the X post. He revealed that the post was made under the cover of trees in a small valley in the Santa Cruz Mountains.
The seventh continent has always been a bleak, unconnected place. Elon Musk’s satellite internet is changing that, and people want to see what life is like there.
Albedo Space wants to launch satellites that can track the movements of and even image individual people. Obviously, privacy is an issue.
At approximately 18:17 CET (17:17 UTC) on Wednesday, February 21, 2024, ESA’s ERS-2 satellite completed its atmospheric reentry over the North Pacific Ocean. No damage to property has been reported.
ESA’s second European Remote Sensing satellite, ERS-2, was launched almost 30 years ago, on April 21, 1995. Together with the almost-identical ERS-1, it provided invaluable long-term data on Earth’s land surfaces, ocean temperatures, ozone layer, and polar ice extent that revolutionized our understanding of the Earth system. It was also called upon to monitor and assist the response to natural disasters.
“The ERS satellites have provided a stream of data which has changed our view of the world in which we live,” said ESA’s Director of Earth Observation Programmes, Simonetta Cheli. “They have provided us with new insights on our planet, the chemistry of our atmosphere, the behavior of our oceans, and the effects of mankind’s activity on our environment – creating new opportunities for scientific research and applications.”
For more than a decade, an abandoned piece of a Japanese rocket has been speeding uncontrolled around Earth, at risk of colliding with active satellites and causing havoc in orbit.
Researchers are working on ways to improve the effectiveness of currently approved bile duct cancer, also called cholangiocarcinoma, treatments and finding early success in the development of more targeted therapies. Read more on the AACR Blog:
To overcome this issue, researchers are exploring next-generation FGFR inhibitors. During the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in January 2024, phase II clinical trial results were announced for tinengotinib, a FGFR1-3 inhibitor that binds to FGFR in a way that blocks FGFR2 fusion and rearrangement, preventing the mutations that cause resistance to treatment. Of the patients in the trial whose tumors had developed resistance to a previous FGFR inhibitor, 37.5% demonstrated a partial response with tumor reductions ranging from 40.7% to 54.6%. A phase III trial for the drug candidate kicked off in December 2023.
Other next-generation FGFR inhibitors are in various stages of development, including RLY-4008 (phase I/II trial), erdafitinib (phase IIa), KIN-3248 (phase I/Ib), derazantinib (phase II), tasurgratinib (phase II), and HMPL-453 (phase II).
Another target researchers have been studying in relation to BTC treatment is the immune checkpoint molecule PD-1. In 2017, the FDA approved pembrolizumab (Keytruda), an immunotherapy that blocks PD-1, for use in several cancer types, including all advanced solid tumors that have a high tumor mutation burden or microsatellite instability. About 5% of patients with cholangiocarcinoma have that type of tumor, according to a study published in ESMO Open.
A European Space Agency satellite is expected to reenter and largely burn up in Earth’s atmosphere on Wednesday morning.
The agency’s Space Debris Office, along with an international surveillance network, is monitoring and tracking the Earth-observing ERS-2 satellite, which is predicted to make its reentry at 3:53 p.m. ET Wednesday, with a 7.5-hour window of uncertainty. The ESA is also providing live updates on its website.
“As the spacecraft’s reentry is ‘natural’, without the possibility to perform manoeuvers, it is impossible to know exactly where and when it will reenter the atmosphere and begin to burn up,” according to a statement from the agency.
NEJM Journal Watch Oncology and Hematology Associate Editor David Ilson was on hand at the 2024 ASCO Gastrointestinal Cancers Symposium and highlights the latest research in colorectal, neuroendocrine, and esophagogastric cancers.
Important new studies with the potential to impact clinical practice were presented at the 2024 ASCO Gastrointestinal Cancers Symposium held January 18 to 20 in San Francisco. NEJM Journal Watch Oncology and Hematology Associate Editor David H. Ilson, MD, PhD, was on hand and reports on some of them.
COLORECTAL CANCER
Researchers presented results from CheckMate 8HW, an industry-sponsored, international, open-label, phase 3 trial evaluating first-line treatments in patients with microsatellite instability (MSI)-high/DNA mismatch repair protein-deficient metastatic colorectal cancer. Patients were randomized to investigator’s choice of chemotherapy (mFOLFOX6 or FOLFIRI, with or without bevacizumab or cetuximab), single-agent nivolumab (240 mg every 4 weeks followed by 480 mg monthly), or nivolumab combined with ipilimumab (1 mg/kg for 4 doses). An interim analysis was presented for the 303 patients treated with chemotherapy or ipilimumab/nivolumab.